The Ministry of Food and Drug Safety announced on the 1st that Pfizer has started reviewing the data as it submitted clinical data for approval of a novel coronavirus infection (COVID-19) vaccine for children aged 5-11.
Pfizer Korea submitted the immunogenicity results and safety data of a clinical trial in which 10 micrograms (㎍), which is one-third of the adult dose, was administered to children aged 5-11 years to the Ministry of Food and Drug Safety on the same day.
The Ministry of Food and Drug Safety plans to review safety and effectiveness based on the submitted clinical data.
Pfizer’s vaccine for children has been approved in the US and Europe.
By Choi Eun-seok, staff reporter [email protected]